UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 49

Sortiert nach

Two Phase 3 Trials of Adalimumab for Hidradenitis Suppurativa

The New England journal of medicine, 2016-08, Vol.375 (5), p.422-434

2016

Volltextzugriff (PDF)

The promise of personalized medicine for hidradenitis suppurativa

British journal of dermatology (1951), 2023-01, Vol.188 (1), p.3-3

Okun, Martin M

2023

Volltextzugriff (PDF)

Patients’ willingness to accept adverse event and cost tradeoffs from oral nicotinamide for reduced risk of non-melanoma skin cancer

The Journal of dermatological treatment, 2023-12, Vol.34 (1), p.2247105-2247105

2023

Volltextzugriff (PDF)

Achieving Hidradenitis Suppurativa Response Score is Associated with Significant Improvement in Clinical and Patient-reported Outcomes: Post Hoc Analysis of Pooled Data From PIONEER I and II

Acta dermato-venereologica, 2018-11, Vol.98 (10), p.932-937

2018

Volltextzugriff (PDF)

Adalimumab treatment optimization for psoriasis: Results of a long-term phase 2/3 Japanese study

Journal of dermatology, 2015-11, Vol.42 (11), p.1042-1052

2015

Volltextzugriff (PDF)

The validity and responsiveness of three quality of life measures in the assessment of psoriasis patients: results of a phase II study

Health and quality of life outcomes, 2006-09, Vol.4 (1), p.71-71, Article 71

2006

Volltextzugriff (PDF)

Switching to adalimumab for psoriasis patients with a suboptimal response to etanercept, methotrexate, or phototherapy: Efficacy and safety results from an open-label study

Journal of the American Academy of Dermatology, 2011-04, Vol.64 (4), p.671-681

2011

Volltextzugriff (PDF)

Long-term adalimumab efficacy in patients with moderate-to-severe hidradenitis suppurativa/acne inversa: 3-year results of a phase 3 open-label extension study

Journal of the American Academy of Dermatology, 2019-01, Vol.80 (1), p.60-69.e2

2019

Volltextzugriff (PDF)

Hidradenitis Suppurativa: Diagnosis and Management in the Emergency Department

The Journal of emergency medicine, 2022-11, Vol.63 (5), p.636-644

2022

Volltextzugriff (PDF)

What causes hidradenitis suppurativa ?—15 years after

Experimental dermatology, 2020-12, Vol.29 (12), p.1154-1170

2020

Volltextzugriff (PDF)

Adalimumab for nail psoriasis: Efficacy and safety from the first 26 weeks of a phase 3, randomized, placebo-controlled trial

Journal of the American Academy of Dermatology, 2018-01, Vol.78 (1), p.90-99.e1

2018

Volltextzugriff (PDF)

Uncovering burden disparity: A comparative analysis of the impact of moderate-to-severe psoriasis and hidradenitis suppurativa

Journal of the American Academy of Dermatology, 2017-12, Vol.77 (6), p.1038-1046

2017

Volltextzugriff (PDF)

Efficacy and safety of the oral Janus kinase 1 inhibitor povorcitinib (INCB054707) in patients with hidradenitis suppurativa in a phase 2, randomized, double-blind, dose-ranging, placebo-controlled study

Journal of the American Academy of Dermatology, 2024-03, Vol.90 (3), p.521-529

2024

Volltextzugriff (PDF)

Psoriasis Area and Severity Index: Nuts and bolts of measuring disease severity in psoriasis

Clinics in dermatology, 2008-11, Vol.26 (6), p.653-656

Okun, Martin M., PhD

2008

Volltextzugriff (PDF)

Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: Double-blind, randomized controlled trial and open-label extension study

Journal of the American Academy of Dermatology, 2006-10, Vol.55 (4), p.598-606

2006

Volltextzugriff (PDF)

Validation of the Physician’s Global Assessment of Fingernail Psoriasis by Rheumatologists Treating Psoriatic Arthritis

Value in health, 2022-09, Vol.25 (9), p.1582-1589

2022

Volltextzugriff (PDF)

Outcome Measures for the Evaluation of Treatment Response in Hidradenitis Suppurativa for Clinical Practice: A HiSTORIC Consensus Statement

JAMA dermatology (Chicago, Ill.), 2023-11, Vol.159 (11), p.1258

2023

Volltextzugriff (PDF)

Poor early response to methotrexate portends inadequate long-term outcomes in patients with moderate-to-severe psoriasis: Evidence from 2 phase 3 clinical trials

Journal of the American Academy of Dermatology, 2017-12, Vol.77 (6), p.1030-1037

2017

Volltextzugriff (PDF)

Efficacy and Safety of Adalimumab among Patients with Moderate to Severe Psoriasis with Co-Morbidities: Subanalysis of Results from a Randomized, Double-Blind, Placebo-Controlled, Phase III Trial

American journal of clinical dermatology, 2011-01, Vol.12 (1), p.51-62

2011

Volltextzugriff (PDF)

Adalimumab treatment is associated with improvement in health-related quality of life in psoriasis: Patient-reported outcomes from a Phase II randomized controlled trial

The Journal of dermatological treatment, 2007, Vol.18 (1), p.25-31

2007

Volltextzugriff (PDF)

No Evidence that Variations in Ambient Solar Ultraviolet Radiation and Psoriasis Severity are Associated

Journal of psoriasis and psoriatic arthritis, 2022-04, Vol.7 (2), p.67-70

2022

Volltextzugriff (PDF)

L1 Interaction Domains of Papillomavirus L2 Necessary for Viral Genome Encapsidation

Journal of Virology, 2001-05, Vol.75 (9), p.4332-4342

2001

Volltextzugriff (PDF)

Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial

Journal of the American Academy of Dermatology, 2008, Vol.58 (1), p.106-115

2008

Volltextzugriff (PDF)

Psoriasis Area and Severity Index : Nuts and bolts of measuring disease severity in psoriasis: Combating Aging Skin: Part II

Clinics in dermatology, 2008, Vol.26 (6), p.653-656

OKUN, Martin M

2008

Volltextzugriff (PDF)

Adalimumab Efficacy in Hidradenitis Suppurativa Patients is Sustained at Least Three Years with Weekly Dosing: Results from a Phase 3 Open-Label Extension Study (PIONEER)

Skin (Milwood, N.Y.), 2017-10, Vol.1, p.s128

2017

Volltextzugriff (PDF)

1 – 25 von 49

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(46)
Mit Volltextzugriff
(45)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(38)
Life Sciences & Biomedicine
(37)
Humans
(31)
Dermatology
(21)
Female
(20)
Male
(18)
Adult
(16)
Middle Aged
(14)
Adalimumab
(11)
Biological And Medical Sciences
(11)
Severity Of Illness Index
(11)
Double-Blind Method
(10)
Medical Sciences
(9)
Treatment Outcome
(9)
Psoriasis - Drug Therapy
(8)
Hidradenitis Suppurativa
(7)
Animals
(6)
Antibodies, Monoclonal - Therapeutic Use
(6)
Antibodies, Monoclonal, Humanized
(6)
Psoriasis
(6)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Two Phase 3 Trials of Adalimumab for Hidradenitis Suppurativa

The promise of personalized medicine for hidradenitis suppurativa

Patients’ willingness to accept adverse event and cost tradeoffs from oral nicotinamide for reduced risk of non-melanoma skin cancer

Achieving Hidradenitis Suppurativa Response Score is Associated with Significant Improvement in Clinical and Patient-reported Outcomes: Post Hoc Analysis of Pooled Data From PIONEER I and II

Adalimumab treatment optimization for psoriasis: Results of a long-term phase 2/3 Japanese study

The validity and responsiveness of three quality of life measures in the assessment of psoriasis patients: results of a phase II study

Switching to adalimumab for psoriasis patients with a suboptimal response to etanercept, methotrexate, or phototherapy: Efficacy and safety results from an open-label study

Long-term adalimumab efficacy in patients with moderate-to-severe hidradenitis suppurativa/acne inversa: 3-year results of a phase 3 open-label extension study

Hidradenitis Suppurativa: Diagnosis and Management in the Emergency Department

What causes hidradenitis suppurativa ?—15 years after

Adalimumab for nail psoriasis: Efficacy and safety from the first 26 weeks of a phase 3, randomized, placebo-controlled trial

Uncovering burden disparity: A comparative analysis of the impact of moderate-to-severe psoriasis and hidradenitis suppurativa

Efficacy and safety of the oral Janus kinase 1 inhibitor povorcitinib (INCB054707) in patients with hidradenitis suppurativa in a phase 2, randomized, double-blind, dose-ranging, placebo-controlled study

Psoriasis Area and Severity Index: Nuts and bolts of measuring disease severity in psoriasis

Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: Double-blind, randomized controlled trial and open-label extension study

Validation of the Physician’s Global Assessment of Fingernail Psoriasis by Rheumatologists Treating Psoriatic Arthritis

Outcome Measures for the Evaluation of Treatment Response in Hidradenitis Suppurativa for Clinical Practice: A HiSTORIC Consensus Statement

Poor early response to methotrexate portends inadequate long-term outcomes in patients with moderate-to-severe psoriasis: Evidence from 2 phase 3 clinical trials

Efficacy and Safety of Adalimumab among Patients with Moderate to Severe Psoriasis with Co-Morbidities: Subanalysis of Results from a Randomized, Double-Blind, Placebo-Controlled, Phase III Trial

Adalimumab treatment is associated with improvement in health-related quality of life in psoriasis: Patient-reported outcomes from a Phase II randomized controlled trial

No Evidence that Variations in Ambient Solar Ultraviolet Radiation and Psoriasis Severity are Associated

L1 Interaction Domains of Papillomavirus L2 Necessary for Viral Genome Encapsidation

Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial

Psoriasis Area and Severity Index : Nuts and bolts of measuring disease severity in psoriasis: Combating Aging Skin: Part II

Adalimumab Efficacy in Hidradenitis Suppurativa Patients is Sustained at Least Three Years with Weekly Dosing: Results from a Phase 3 Open-Label Extension Study (PIONEER)

Suchergebnisse filtern